Impact of Uterotonic Agents on Isolated Human Myometrium

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Postpartum Hemorrhage
Interventions
DRUG

Oxytocin

Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

DRUG

Ergonovine

Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

DRUG

Carboprost

Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

DRUG

Oxytocin and Ergonovine

Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

DRUG

Oxytocin and Carboprost

Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

Trial Locations (1)

M5G 1X5

Mount Sinai Hospital, Toronto

All Listed Sponsors
lead

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

OTHER

NCT00989027 - Impact of Uterotonic Agents on Isolated Human Myometrium | Biotech Hunter | Biotech Hunter